Yukhta T.V.,Nn Petrov Research Institute Of Oncology |
Kazantsev I.V.,Rm Gorbacheva Institute Of Pediatric Oncology Hematology And Transplantation |
Punanov Yu.A.,Nn Petrov Research Institute Of Oncology |
Safonova S.A.,Nn Petrov Research Institute Of Oncology |
And 4 more authors.
Voprosy Onkologii | Year: 2014
For the period between 1995 and 2010, 60 patients with tumors of Ewing's sarcoma family were treated (m-36, f-24) aged from 2 to 17 years (med. - 11.2 years). According to treatment program patients were divided into 3 groups. The first group (I) included 24 children who had received therapy in 1995-2002 in regard to a modified protocol T9. The second group (II) included 10 children treated in 1997-2005 by protocol EICESS-92. The third group (III) included 26 patients treated from 2003 to 2010 by protocol Euro-EWING99. Patients with a generalization of the process in each group were 4 (16.6%) 2 (20%) and 16 (62%), respectively. High- dose poly chemotherapy with autologous transplantation of hematopoietic stem cells was performed in 16 children of group III with unfavorable prognostic factors (in this case metastases to the lung or pleura were observed in 13, central localization - in 9, the tumor volume of > 200 cm3 in 9 patients). Among patients with localized forms the highest rates of 5-year survival were marked for patients with distal tumor localization (82.5%) and in patients with a tumor volume less than 200 cm3 (72.3%). All patients of I and II groups with generalized forms of tumors of Ewing's sarcoma family died by 30 months of observation after disease progression. 16 patients of group III treated by high-dose poly chemotherapy with autologous transplantation of hematopoietic stem cells overall survival, with an average duration of observation 37 months (12-60 months) was 43.1% and disease-free survival was 28.7%. Source